Sort
21,453 grants matching “tuberculosis”
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
$2,659,562John McLeod Griffiss · Icon Government And Public Health Solutions, Inc. · N01 · FY2012 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression
$2,658,286David Alland · Rutgers Biomedical And Health Sciences · U19 · FY2023 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression
$2,658,286David Alland · Rbhs-New Jersey Medical School · U19 · FY2022 · AI
Enhancing SEBLAB Research Productivity, Operations and Core Laboratory Support
$2,655,736Sixto Manuel Leal · University Of Alabama At Birmingham · UC7 · FY2025 · AI
C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study
$2,655,299Payam Nahid · University Of California, San Francisco · U01 · FY2024 · AI
Columbia Collaborative HIV/AIDS Clinical Trials Unit
$2,654,816Magdalena Elzbieta Sobieszczyk · Columbia University Health Sciences · UM1 · FY2022 · AI
Scientific Core - Compound Optimization and Prioritization.
$2,652,211Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2021 · AI
Durban International Clinical Trials Unit
$2,651,567Umesh G Lalloo · Ukzn Innovation · U01 · FY2010 · AI
Structural Genomics of Persistence Targets from M. tuberculosis
$2,650,000James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2006 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)
$2,649,501David W Haas · Vanderbilt University Medical Center · UM1 · FY2024 · AI
The Asia-Pacific HIV Research Collaboration
$2,648,236David A Cooper · Foundation For Aids Research · U01 · FY2012 · AI
Clinical Proteomics
$2,645,123Joanna Hunter · Caprion Proteomics, Inc. · N01 · FY2011 · AI
HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)
$2,642,740Stephen A Spector · University Of California, San Diego · UM1 · FY2014 · AI
Pathway Analysis in Tuberculosis
$2,639,702Sabine Ehrt · Weill Medical Coll Of Cornell Univ · P01 · FY2020 · AI
Host Pathogen Variation & TB Pathogenesis
$2,638,886Thomas R Hawn · University Of Washington · U19 · FY2021 · AI
PS10-10121, HQ (PEPFAR): BUILDING GLOBAL CAPACITY FOR DIAGNOSTIC TESTING OF TUBERCULOSIS, MALARIA AND HIV
$2,635,000Heidi Albert · Foundation/Innovative New Diagnostics · U2G · FY2015 · PS
San Francisco Bay Clinical Trials Unit
$2,634,428Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2019 · AI
Support for Enhancement Excellence in Research at UPR RP
$2,631,086University Of Puerto Rico Rio Piedras · S06 · FY2004 · GM
TUBERCULOSIS ELIMINATION & LABORATORY
$2,628,630Rose-Marie F Sales · Georgia State Departmentof Public Health · U52 · FY2014 · PS
Columbia Collaborative HIV/AIDS Clinical Trials Unit
$2,623,185Magdalena Elzbieta Sobieszczyk · Columbia University Health Sciences · UM1 · FY2024 · AI
Stellenbosch University Clinical Trials Unit (SUN-CTU)
$2,619,827Mark Fredric Cotton · Stellenbosch University · UM1 · FY2019 · AI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis
$2,619,058George Louis Drusano · University Of Florida · P01 · FY2020 · AI
Advanced Mass Spectrometry Facility
$2,614,730David Anderson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIC · FY2012 · DK
Metabolic determinants of Mtb virulence, vulnerability and variation
$2,610,899David Branch Moody · Brigham And Women'S Hospital · U19 · FY2024 · AI
Glycoengineering In Vivo
$2,610,000Robert McCullough Anthony · Massachusetts General Hospital · DP2 · FY2014 · AR